SCHEMBL4842844

SCHEMBL4842844

Clc1cnc2[nH]c(-c3ccc(NCCN4CCOCC4)cc3)nc2c1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKE Q14164 1/20 0.45
TBK1 Q9UHD2 1/20 0.45
KDM4E B2RXH2 5/20 0.43
ALDH1A1 P00352 4/20 0.43
RAB9A P51151 2/20 0.43
HTT P42858 2/20 0.43
FYN P06241 1/20 0.42
EGFR P00533 2/20 0.42
NPC1 O15118 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CYP1A2 P05177 3/20 0.41
CYP3A4 P08684 3/20 0.41
CYP2D6 P10635 3/20 0.41
TSHR P16473 3/20 0.41
LMNA P02545 2/20 0.41
CYP2C19 P33261 2/20 0.41
CLK4 Q9HAZ1 2/20 0.41
HIF1A Q16665 1/20 0.41
ACHE P22303 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4842934 0.87 MEN1 (0.49) IKBKETBK1KDM4EALDH1A1RAB9A
SCHEMBL4841957 0.84 TBK1 (0.64) IKBKETBK1KDM4EALDH1A1RAB9A
SCHEMBL4838835 0.80 TBK1 (0.64) IKBKETBK1KDM4EALDH1A1RAB9A
SCHEMBL5263227 0.76 IKBKE (0.41) IKBKETBK1KDM4EALDH1A1FYN
SCHEMBL4842205 0.76 IKBKE (0.41) IKBKETBK1KDM4EALDH1A1FYN
SCHEMBL3087712 0.74 PARP1 (0.49) IKBKETBK1HIF1AACHE
SCHEMBL4838086 0.73 TBK1 (0.63) IKBKETBK1KDM4EALDH1A1RAB9A
SCHEMBL4150322 0.73 KDM4E (0.47) KDM4EALDH1A1RAB9AHTTNPC1
SCHEMBL5256467 0.72 MAPT (0.41) KDM4EALDH1A1NPC1L3MBTL1LMNA
SCHEMBL4844041 0.72 TBK1 (0.59) IKBKETBK1KDM4EALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7410966-B2 Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2008-08-12 US claimed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP claimed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US claimed
US-7410966-B2 Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2008-08-12 US disclosed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP disclosed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261333-A1 Use of and some novel imidazopyridines ITK, CSNK1A1, RPS6KA1 IKBKE 95/4885TBK1 1029/4885KDM4E 2903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.